CureVac N.V. Form 6-K (June 4, 2021)

Summary

A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of June, 2021, Commission File Number 001-39446. It states that on June 4, 2021 the company convened the annual general meeting of shareholders for June 24, 2021 and made certain other materials available to its shareholders in connection with the meeting. The exhibit index lists a convening notice including agenda and explanatory notes as Exhibit 99.1 and a voting proxy as Exhibit 99.2. The report is signed by Franz-Werner Haas, LLD, LLM, Chief Executive Officer.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE
ISSUER

PURSUANT TO RULE 13a-16
OR 15d-16 OF THE

SECURITIES EXCHANGE ACT
OF 1934

For the month of June, 2021

Commission File Number: 001-39446

CureVac N.V.

( Exact Name of Registrant as Specified in Its
Charter )

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F | x | Form 40-F | ¨

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes | ¨ | No | x

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes | ¨ | No | x

On June 4, 2021, CureVac N.V. (the “Company”)
convened the annual general meeting of shareholders to be held on June 24, 2021 and made available to its shareholders certain other materials
in connection with such meeting.

The information in this Form 6-K (including Exhibit
99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933 or the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CUREVAC N.V.
By: | /s/ Franz-Werner Haas, LLD, LLM
Chief Executive Officer

Date: June 4, 2021

EXHIBIT INDEX

EXHIBIT NO. | DESCRIPTION
99.1 | Convening notice including agenda and explanatory notes
99.2 | Voting proxy

File and source

File

SEC_CVAC_6-K_filed2021-06-04_0001104659-21-077064.htm

Size

13,740 bytes

SHA-256

768266eb4e1af11854174c16870f249f4f417993274daab476ceeab011aad110

Our copy

SEC_CVAC_6-K_filed2021-06-04_0001104659-21-077064.htm

Original

www.sec.gov